Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Cheah, Agnes Loo Y ^a,b,c   Peel, Trisha ^d   Howden, Benjamin P ^c,d   Spelman, Denis ^a,b,e   Grayson, M L ^c,d   Nation, Roger L ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b Department of Infectious Diseases The Alfred ^*  (Australia)

^c AUSTIN HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Microbiology Unit   (Australia)

Author keywords

Bacteraemia; Enterococci; Vancomycin resistant; Vancomycin susceptible

Indexed keywords

AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIMENTIN; VANCOMYCIN;

ADULT; AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CATHETER INFECTION; CHRONIC DISEASE SCORE SPECIFIC FOR VRE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HOSPITAL ADMISSION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PUBLIC HOSPITAL; SCORING SYSTEM; TERTIARY CARE CENTER; TREATMENT DURATION; URINARY CATHETER; VANB GENE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS; ANTIBIOTIC RESISTANCE; CASE CONTROL STUDY; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AUSTRALIA; BACTEREMIA; CASE-CONTROL STUDIES; ENTEROCOCCUS; FEMALE; GENOTYPE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN RESISTANCE; VANCOMYCIN-RESISTANT ENTEROCOCCI; VICTORIA;

EID: 84903244138     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-353     Document Type: Article

References (49)

1. Hidron Alicia I, Edwards Jonathan R, Patel J, Horan Teresa C, Sievert Dawn M, Pollock Daniel A, Fridkin Scott K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. 10.1086/591861, 18947320.
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant Enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007, 58:163-170. 10.1016/j.diagmicrobio.2006.12.022, 17368801.
3. Australian Group for Antimicrobial Resistance (AGAR) posters and publications website. Vancomycin resistant enterococci in Australia: results of the AGAR surveys 1995 to 2010 http://www.agargroup.org/files/VRE%20in%20Australia.pdf. Accessed 7 June, 2012.
4. Webb M, Riley L, Roberts R. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001, 33:445-452. 10.1086/321891, 11462178.
5. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant Enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol 1998, 36:2187-2190. 105003, 9665988.
6. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000, 19:816-822. 10.1007/s100960000390, 11152305.
7. Stuart RL, Kotsanas D, Webb B, Vandergraaf S, Gillespie EE, Hogg GG, Korman TM. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust 2011, 195:530-533. 10.5694/mja11.10724, 22060088.
8. Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust 2005, 182:492.
9. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994, 38:1363-1367. 10.1128/AAC.38.6.1363, 188211, 8092838.
10. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126-1133. 10.1093/clinids/20.5.1126, 7619987.
11. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995, 172:993-1000. 10.1093/infdis/172.4.993, 7561221.
12. Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles C, Vindel A, Canton E, Gobernado M. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000, 19:742-749. 10.1007/s100960000360, 11117637.
13. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000, 36:145-158. 10.1016/S0732-8893(99)00136-4, 10729656.
14. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001, 135(7):484-492. 10.7326/0003-4819-135-7-200110020-00007, 11578151.
15. Roghmann M-C, McCarter RJ, Brewrink J, Cross AS, Morris JG. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant Enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997, 25:1056-1059. 10.1086/516112, 9402356.
16. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med 1998, 158:522-527. 10.1001/archinte.158.5.522, 9508230.
17. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998, 26:1127-1133. 10.1086/520311, 9597241.
18. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999, 20:660-663. 10.1086/501561, 10530642.
19. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999, 20:318-323. 10.1086/501624, 10349947.
20. Zaas A, Song X, Tucker P, Perl T. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant Enterococci. Clin Infect Dis 2002, 35:1139-1146. 10.1086/342904, 12410472.
21. de Perio MA, Yarnold Paul R, Warren J, Noskin Gary A. Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. Infect Contr Hosp Epidemiol 2006, 27:28-33.
22. Olivier C, Blake R, Steed L, Salgado C. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol 2008, 29:404-409. 10.1086/587647, 18419361.
23. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, Johnson JA, Dowling TC, Polish LB, Schwalbe RS. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995, 123:250-259. 10.7326/0003-4819-123-4-199508150-00002, 7611590.
24. Papanicolaou G, Meyers B, Meyers J, Mendelson M, Lou W, Emre S, Sheiner P, Miller C. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996, 23:760-766. 10.1093/clinids/23.4.760, 8909841.
25. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996, 23:767-772. 10.1093/clinids/23.4.767, 8909842.
26. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002, 8:802-807. 10.3201/eid0808.010418, 2732508, 12141965.
27. Chavers LS, Moser SA, Funkhouser E, Benjamin WH, Chavers P, Stamm AM, Waites KB. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant Enterococci. Microb Drug Resist 2003, 9:S69-S77. 10.1089/107662903322541928, 14633370.
28. Nguyen GC, Leung W, Weizman AV. Increased risk of vancomycin-resistant Enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2011, 17:1338-1342. 10.1002/ibd.21519, 21560197.
29. McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, Baddley JW, Pappas PG, Miller LG. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol 2012, 33:718-724. 10.1086/666331, 3879097, 22669234.
30. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007, 79:226-233. 10.1111/j.1600-0609.2007.00911.x, 17655696.
31. Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol Infect 2011, 18:388-394.
32. Patel R. Clinical impact of vancomycin-resistant Enterococci. J Antimicrob Chemother 2003, 51(iii):13-21.
33. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Contr Hosp Epidemiol 2005, 26:346-351.
34. Barrall DT, Kenney PR, Slotman GJ, Burchard KW. Enterococcal bacteremia in surgical patients. Arch Surg 1985, 120:57-63. 10.1001/archsurg.1985.01390250049008, 3966874.
35. Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F. Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia: a matched case-control study. Arch Intern Med 1993, 153:1581-1586. 10.1001/archinte.1993.00410130103010, 8323421.
36. Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola A, Gualandi F, Van Lint M, Dominietto A, Lamparelli T, Cappellano P, Bacigalupo A, Viscoli C. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2010, 12:505-512. 10.1111/j.1399-3062.2010.00544.x, 20636482.
37. Gray J, Marsh PJ, Stewart D, Pedler SJ. Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect 1994, 27:179-186. 10.1016/0195-6701(94)90125-2, 7963458.
38. Caballero-Granado FJ, Becerril B, Cisneros JM, Cuberos L, Moreno I, Pachon J. Case-control study of risk factors for the development of enterococcal bacteremia. Eur J Clin Microbiol Infect Dis 2001, 20:83-90.
39. Sitges-Serra A, Lopez M, Girvent M, Almirall S, Sancho J. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002, 89:361-367. 10.1046/j.0007-1323.2001.02023.x, 11872065.
40. Patel R, Badley AD, Larson-Keller J, Harmsen WS, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Portela D, Cockerill FR, Paya CV. Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation 1996, 61:1192-1197. 10.1097/00007890-199604270-00013, 8610417.
41. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995, 33:24-27. 227872, 7699051.
42. McGregor JC, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006, 59:1266-1273. 10.1016/j.jclinepi.2006.01.016, 17098569.
43. Pregibon D. Goodness of link tests for generalized linear models. J Roy Stat Soc C Appl Stat 1980, 29:15-24.
44. Suppola JP, Kuikka A, Vaara M, Valtonen VV. Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia. Scand J Infect Dis 1998, 30:153-157. 10.1080/003655498750003546, 9730302.
45. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. Effect of antibiotic therapy on the density of vancomycin-resistant Enterococci in the stool of colonized patients. New Engl J Med 2000, 343:1925-1932. 10.1056/NEJM200012283432604, 11136263.
46. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012, 55:905-914. 10.1093/cid/cis580, 3657523, 22718773.
47. Harris A, Samore M, Lipsitch M, Kaye K, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002, 34:1558-1563. 10.1086/340533, 12032889.
48. Timmers GJ, van der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM, Huijgens PC. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 2002, 116:826-833. 10.1046/j.0007-1048.2002.03339.x, 11886387.
49. Sedgwick P. Case-control studies: sources of bias. BMJ 2011, 343:d6284.